FY2024 EPS Estimates for Journey Medical Boosted by B. Riley

Journey Medical Co. (NASDAQ:DERM) – Stock analysts at B. Riley raised their FY2024 earnings per share (EPS) estimates for Journey Medical in a research note issued on Monday, November 18th. B. Riley analyst K. Patel now expects that the company will earn ($1.04) per share for the year, up from their prior forecast of ($1.13). The consensus estimate for Journey Medical’s current full-year earnings is ($1.03) per share. B. Riley also issued estimates for Journey Medical’s FY2025 earnings at ($0.61) EPS, FY2026 earnings at ($0.05) EPS, FY2027 earnings at $0.39 EPS and FY2028 earnings at $0.93 EPS.

DERM has been the subject of several other research reports. Rodman & Renshaw started coverage on shares of Journey Medical in a research note on Thursday, August 22nd. They issued a “buy” rating and a $9.00 target price for the company. Lake Street Capital started coverage on Journey Medical in a report on Friday, September 6th. They set a “buy” rating and a $9.00 price objective on the stock. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $9.38.

Journey Medical Stock Up 5.9 %

DERM opened at $5.35 on Wednesday. The firm has a market cap of $110.91 million, a price-to-earnings ratio of -5.84 and a beta of 0.92. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.03 and a current ratio of 1.38. The firm’s 50-day simple moving average is $5.62 and its 200-day simple moving average is $5.08. Journey Medical has a twelve month low of $2.85 and a twelve month high of $8.11.

Institutional Trading of Journey Medical

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Cambridge Investment Research Advisors Inc. bought a new stake in shares of Journey Medical in the 2nd quarter valued at about $1,664,000. Acadian Asset Management LLC grew its position in shares of Journey Medical by 687.5% during the 1st quarter. Acadian Asset Management LLC now owns 222,663 shares of the company’s stock worth $817,000 after purchasing an additional 194,389 shares in the last quarter. PVG Asset Management Corp acquired a new position in Journey Medical in the second quarter valued at about $894,000. Rosalind Advisors Inc. bought a new stake in shares of Journey Medical during the 2nd quarter worth approximately $644,000. Finally, Heron Bay Capital Management bought a new stake in shares of Journey Medical during the first quarter worth $124,000. Institutional investors and hedge funds own 7.25% of the company’s stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.